Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by Corvus Pharmaceuticals, Inc. Credit Suisse, Jefferies, Guggenheim Securities…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
